De hyppigst rapporterede bivirkninger, der ses i fase 3- forsøgene ved anbefalet dosis uanset hyppighed sammenlignet med optimal baggrundsbehandling (OB) alene, er diarré, kvalme og
The most frequently reported adverse reactions occurring in the Phase 3 studies at the recommended dose regardless of the incidence compared to OBT alone were diarrhoea, nausea and headache.